Digitoxin Inhibits Cancer Cell Growth at Concentrations Found in Cardiac Patients

Researchers at the University of Seville in Spain have discovered that digitoxin, a cardiac glycoside, can inhibit cancer cell growth at concentrations commonly found in patients with cardiac disease. The study, published in the Journal of Natural Products, found that digitoxin was the most active compound in inhibiting growth in three human cancer cell lines, with IC50 values within or below the concentration range seen in patients with cardiac disease.

Key Takeaways:

• Digitoxin, a cardiac glycoside, has been found to inhibit cancer cell growth at concentrations commonly found in patients with cardiac disease.
• The study used three human cancer cell lines and found that digitoxin was the most active compound in inhibiting growth, with IC50 values of 3-33 nM.
• A renal adenocarcinoma cancer cell line (TK-10) was hypersensitive to digitoxin, and the toxicity was mediated by apoptosis.
• The study also found that digitoxin induced levels of DNA-topoisomerase II cleavable complexes similar to etoposide, a topoisomerase II poison used in cancer chemotherapy.
• The researchers concluded that digitoxin has potential as a cancer drug, and further studies are needed to explore its therapeutic applications.

Statistics:

• IC50 values for digitoxin in inhibiting growth in three human cancer cell lines were between 3-33 nM.
• The concentration range of digitoxin in patients with cardiac disease is 20-33 nM.
• The study found that digitoxin induced levels of DNA-topoisomerase II cleavable complexes similar to etoposide, a topoisomerase II poison used in cancer chemotherapy.
• The researchers used the TARDIS cell assay to study the effects of digitoxin on cancer cells.